Free Trial

Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics logo
$120.69 +0.39 (+0.32%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AXSM vs. JAZZ, TEVA, GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, and MRNA

Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), and Moderna (MRNA). These companies are all part of the "medical" sector.

Axsome Therapeutics vs. Its Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals-9.91% 5.02% 1.73%
Axsome Therapeutics -49.88%-283.22%-33.06%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 17 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.94 beat Jazz Pharmaceuticals' score of 0.70 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
11 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive
Axsome Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.09B2.06$560.12M-$6.73-20.57
Axsome Therapeutics$385.69M15.61-$287.22M-$5.07-23.80

Jazz Pharmaceuticals currently has a consensus target price of $178.93, suggesting a potential upside of 29.24%. Axsome Therapeutics has a consensus target price of $177.93, suggesting a potential upside of 47.43%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.00

Jazz Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Summary

Jazz Pharmaceuticals and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXSM vs. The Competition

MetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.02B$3.35B$6.13B$10.62B
Dividend YieldN/A2.28%5.66%4.70%
P/E Ratio-23.7922.1385.9727.20
Price / Sales15.61267.29531.49204.35
Price / CashN/A46.3226.3031.12
Price / Book102.289.9712.726.67
Net Income-$287.22M-$52.35M$3.30B$276.04M
7 Day Performance2.61%6.25%4.30%3.16%
1 Month Performance-3.58%11.93%7.58%10.56%
1 Year Performance39.38%25.16%73.65%33.67%

Axsome Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXSM
Axsome Therapeutics
4.7926 of 5 stars
$120.69
+0.3%
$177.93
+47.4%
+38.9%$6.02B$385.69M-23.79380Analyst Revision
JAZZ
Jazz Pharmaceuticals
4.6853 of 5 stars
$129.02
+1.6%
$178.93
+38.7%
+27.5%$7.83B$4.07B-19.172,800Insider Trade
TEVA
Teva Pharmaceutical Industries
3.1703 of 5 stars
$19.17
+4.5%
$25.14
+31.2%
+14.4%$21.99B$16.54B-119.8136,830Analyst Forecast
GMAB
Genmab A/S
4.1388 of 5 stars
$29.33
+0.9%
$40.00
+36.4%
+42.9%$18.82B$3.12B14.742,682High Trading Volume
SMMT
Summit Therapeutics
3.0487 of 5 stars
$21.16
+1.0%
$31.29
+47.9%
+12.3%$15.72B$700K-20.95110
ASND
Ascendis Pharma A/S
3.2716 of 5 stars
$191.60
-0.2%
$244.36
+27.5%
+43.0%$11.81B$393.54M-37.131,017
RDY
Dr. Reddy's Laboratories
3.2606 of 5 stars
$13.96
-1.9%
$16.95
+21.5%
-9.5%$11.65B$3.81B21.1427,811Positive News
VTRS
Viatris
1.1631 of 5 stars
$9.62
+1.1%
$10.40
+8.1%
-12.1%$11.22B$14.74B-3.3232,000
ROIV
Roivant Sciences
3.4279 of 5 stars
$15.10
-0.5%
$19.94
+32.0%
+42.1%$10.31B$29.05M-21.57860
BBIO
BridgeBio Pharma
4.1948 of 5 stars
$51.96
+3.8%
$63.94
+23.1%
+109.5%$9.93B$221.90M-12.70400
MRNA
Moderna
4.3419 of 5 stars
$25.33
+3.4%
$41.81
+65.1%
-52.7%$9.86B$3.24B-3.365,800

Related Companies and Tools


This page (NASDAQ:AXSM) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners